MediMabBio key facts
- Developer of healthcare immunotherapies designed to treat serious diseases such as cancer and autoimmune disorders.
- It has raised $37.9M; the latest was Later Stage VC ($18.0M) in Oct 2025.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Smilegate Investment, Posco Investment, iM Investment Partners — 19 tracked in total.
- Status: Privately Held (backing).
Who backs MediMabBio
19+- ·The complete investor list: 19 names
- ·Watch MediMabBio: the Monday email on marks, rounds and moves
MediMabBio funding rounds
No funding rounds for MediMabBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MediMabBio investors
19 investors are on record for MediMabBio, including Tech Incubator Program for Startup, KB Investment, Smilegate Investment and Posco Investment. By type, the record holds 6 venture capital firms and 1 hedge fund.
About MediMabBio
Developer of healthcare immunotherapies designed to treat serious diseases such as cancer and autoimmune disorders. The company offers engineered monoclonal antibodies, cytokine-antibody fusion proteins, and T-cell-targeted biologics, enabling pharmaceutical collaborators and clinical researchers to access next-generation immuno-oncology candidates and biologics with precision-designed functionalities.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2017
- Employees
- 16
- Website
- medimabbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
MediMabBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.